A new FDA-approved treatment allows heart failure and chronic kidney disease patients to manage dangerous fluid buildup at home, potentially preventing emergency room visits and hospitalizations. Furoscix ReadyFlow, an autoinjector developed by MannKind Corp., delivers the diuretic furosemide subcutaneously (under the skin) with the same effectiveness as intravenous administration, offering patients a faster, simpler alternative to hospital-based treatment.

What Is Furoscix ReadyFlow and How Does It Work?

Furoscix ReadyFlow is designed to address a common problem for people living with heart failure or chronic kidney disease (CKD): fluid overload, also called edema. When the heart or kidneys aren't functioning properly, fluid can accumulate in the body, causing swelling, shortness of breath, and other serious complications. The new autoinjector delivers an 80 mg/mL dose of furosemide, a diuretic medication that helps the body eliminate excess fluid through urine.

What makes this treatment different is its speed and simplicity. The injection takes less than 10 seconds to administer, and patients can do it themselves at home. The medication is absorbed into the bloodstream and symptom relief may begin in an hour or less. Clinical data showed that Furoscix ReadyFlow achieved equivalent urine output, sodium excretion, and potassium excretion compared to intravenous furosemide at 6, 8, and 12 hours after administration.

Why Does This Matter for Heart Failure and Kidney Disease Patients?

For patients with heart failure or chronic kidney disease, fluid overload can quickly spiral into a crisis. Without timely intervention, worsening symptoms often lead to emergency department visits, hospitalizations, or readmissions. Furoscix ReadyFlow aims to break this cycle by allowing patients to address fluid buildup earlier, before symptoms become severe enough to require hospitalization.

"Too often, patients living with heart failure or chronic kidney disease find themselves caught in a cycle of worsening fluid overload that can disrupt daily life and lead to ER visits and hospitalization. An at-home option that delivers similar IV-equivalent furosemide exposure through a simple autoinjector gives clinicians an important new tool to intervene as soon as signs and symptoms of fluid overload appear," said Hunter Champion, MD, PhD, Director of the Heart Failure and Pulmonary Hypertension program at Southeastern Cardiology Associates in Columbus, Georgia.

Hunter Champion, MD, PhD, Director of Heart Failure and Pulmonary Hypertension, Southeastern Cardiology Associates

How to Recognize When You Need Fluid Management Treatment

Patients with heart failure or chronic kidney disease should be aware of warning signs that fluid is accumulating in their bodies. Early recognition allows for faster intervention with treatments like Furoscix ReadyFlow.

• Swelling in Legs and Ankles: Fluid retention often first appears as puffiness or swelling in the lower extremities, which may worsen throughout the day.
• Shortness of Breath: Excess fluid can accumulate in the lungs, making it harder to breathe, especially during physical activity or when lying flat.
• Sudden Weight Gain: Rapid weight gain over a few days, such as 2 to 3 pounds or more, can indicate fluid accumulation and warrants medical attention.
• Fatigue and Weakness: Fluid overload can reduce the heart's ability to pump blood efficiently, leading to persistent tiredness and reduced exercise tolerance.

Patients who notice these symptoms should contact their healthcare provider promptly. With Furoscix ReadyFlow now available, clinicians have a new option to intervene quickly in outpatient, post-discharge, and home-based care settings.

When Will Furoscix ReadyFlow Be Available?

Furoscix ReadyFlow is expected to be commercially available in the United States by the end of August 2026. The treatment will be offered to cardiologists, nephrologists, outpatient heart failure clinics, and integrated delivery networks (IDN).

This approval builds on the success of the original Furoscix, which was approved by the FDA in 2022 for heart failure patients and in 2025 for chronic kidney disease patients. That version uses an on-body infusor that requires five hours of administration time. The new ReadyFlow autoinjector dramatically reduces administration time to 10 seconds or less, making it far more convenient for patients.

The FDA approval of Furoscix ReadyFlow is supported by clinical data demonstrating that the treatment was generally well tolerated, with a safety profile consistent with known effects of oral and intravenous furosemide. This means patients can expect similar side effects and benefits to what they would experience with traditional IV or oral diuretic therapy.

For millions of people managing heart failure or chronic kidney disease, this new treatment option represents a meaningful shift in how fluid overload can be managed. By enabling earlier intervention outside the hospital setting, Furoscix ReadyFlow has the potential to reduce the burden of emergency visits and hospitalizations while helping patients maintain better control of their condition at home.